Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Advances in Itch Biology, Sensory Neurons, and Emerging Therapeutic Targets
Description
The talk explained itch as a peripheral sensory process that begins in the skin and is relayed by specific sensory neurons to the spinal cord and brain, with scratching acting as a reflex that can itself drive inflammation. Itch was presented as highly specific yet evolutionarily underappreciated, often worse than chronic pain because it promotes wakefulness and compulsive scratching. The speaker described distinct itch mediators and neural markers, including histamine, IL-31, and receptors such as MRGPRD, MRGPRA3, and others, and argued that type 2 cytokine signaling is not just inflammatory but also neuromodulatory. Emerging therapies targeting IL-31, IL-4 receptor, and JAK pathways were highlighted, along with evidence that JAK1, JAK2, and TYK2 signaling in sensory neurons may be important in itch, psoriasis, psoriatic arthritis, and chronic pruritus of unknown origin. The talk also covered newer findings showing roles for IL-3 from gamma delta T cells, IL-17-driven hyperinnervation in psoriasis, bacterial proteases such as staph aureus V8 protease, and the possibility that sensory neurons can develop “itch memory.” Overall, the speaker emphasized that ongoing basic and translational research is rapidly uncovering new neural and immune targets that should lead to more itch treatments in the future.
View moreConclusions
- Itch is primarily encoded in the skin and peripheral sensory neurons rather than being a purely brain-based sensation.
- Itch is a distinct sensory pathway with specialized pruriceptors and receptor signatures, although human itch neurons are often polymodal rather than fully dedicated.
- A major conclusion is that itch reflects inflammatory signaling, especially type 2 immune pathways, making scratching and itch part of a neuroimmune circuit.
- Cytokine pathways such as IL-31, IL-4, IL-3, and IL-17 can drive itch directly or indirectly, often through JAK-dependent signaling in sensory neurons.
- JAK inhibitors and cytokine-blocking biologics appear to work not only as anti-inflammatory agents but also as true neuromodulators for itch.
- Clinical data suggest strong efficacy of agents such as nemolizumab and dupilumab across several itch disorders, including atopic dermatitis, prurigo nodularis, and possibly chronic pruritus of unknown origin.
- Scratching is not merely a response to itch; it can amplify inflammation and neuropeptide release, creating a self-reinforcing itch-inflammation loop.
- Some itch states may arise from neural rewiring or hyperinnervation, particularly in psoriasis, rather than from inflammation alone.
- Bacterial and protease signals can directly activate pruriceptors and provoke itch independent of classical immune circuits.
- Sensory neurons may exhibit a form of memory or sensitization after allergen/protease exposure, helping explain persistent or amplified itch responses over time.
- The field is moving toward identifying new pruritic targets, suggesting that additional itch therapies will continue to emerge beyond current biologics and JAK inhibitors.
- Tamari and Ver Heul et al. Ann Rev Immunol 2021
- Liu et al. Cell 2009
- Han et al. Nat Neuro 2013
- Mishra et al. Cell 2013
- Sun and Chen Nature 2007
- Mu et al. Science 2017
- Sonkoly et al. JACI 2006
- Usoskin et al. Nat Neurosci 2015
- Oetjen et al. Cell 2017
- Cevikbas et al. JACI 2014
- Solinski et al. Cell Rep 2019
- Wang et al. Immunity 2019
- Kim et al. Cell 2024
- Nguyen et al. eLife 2021
- Trier et al. J Immunol 2019
- Kabashima et al. NEJM 2020
- Stander et al. NEJM 2020
- Yosipovitch et al. Nat Med 2023
- Jeon et al. J Dermatol Treat 2021
- Flayer et al. Nature 2024
- Delaleu et al. PNAS 2025
- Ramsden et al. Sci Signal 2017
- Liu et al. Science 2025
- Deng et al. Cell 2023
- Tamari et al. Ann Rev Immunol 2021